PRCT Stock Forecast & Price Target

PROCEPT BioRobotics Corp has demonstrated consistent growth in utilization, with an average increase of approximately 6.1% per quarter over the last six quarters, indicating a positive trajectory for its systems. In early 2024, the company focused on controlling operating expenses to grow at half the rate of top-line revenue growth, which has been positively received by the market as it signals a clearer pathway to profitability. Additionally, the company reported a strong placement of capital systems, with 58 new system installations in the recent quarter, surpassing previous guidance and reflecting robust demand even amid a somewhat challenging macroeconomic environment.

PROCEPT BioRobotics Corp has experienced a significant decline in its stock price, with shares down approximately 54% year-to-date, suggesting persistent challenges in its financial performance despite its efforts to meet and raise internal guidance. Key downside risks identified include a potential decrease in demand for capital equipment, which could negatively affect sales, as well as reduced handpiece usage by customers and increasing competition within the surgical robotics market. Additionally, changes in reimbursement policies for the company's Aquablation therapy could further pressure revenue, contributing to an overall negative outlook for the company's financial health.